{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:17:48Z","timestamp":1792642668268,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2021,1,14]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Therapeutic strategies silencing and reducing the hepatitis B virus (HBV) reservoir, the covalently closed circular DNA (cccDNA), have the potential to cure chronic HBV infection. We aimed to investigate the impact of small interferring RNA (siRNA) targeting all HBV transcripts or pegylated interferon-\u03b1 (peg-IFN\u03b1) on the viral regulatory HBx protein and the structural maintenance of chromosome 5\/6 complex (SMC5\/6), a host factor suppressing cccDNA transcription. In particular, we assessed whether interventions lowering HBV transcripts can achieve and maintain silencing of cccDNA transcription in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>HBV-infected human liver chimeric mice were treated with siRNA or peg-IFN\u03b1. Virological and host changes were analysed at the end of treatment and during the rebound phase by qualitative PCR, ELISA, immunoblotting and chromatin immunoprecipitation. RNA in situ hybridisation was combined with immunofluorescence to detect SMC6 and HBV RNAs at single cell level. The entry inhibitor myrcludex-B was used during the rebound phase to avoid new infection events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both siRNA and peg-IFN\u03b1 strongly reduced all HBV markers, including HBx levels, thus enabling the reappearance of SMC5\/6 in hepatocytes that achieved HBV-RNA negativisation and SMC5\/6 association with the cccDNA. Only IFN reduced cccDNA loads and enhanced IFN-stimulated genes. However, the antiviral effects did not persist off treatment and SMC5\/6 was again degraded. Remarkably, the blockade of viral entry that started at the end of treatment hindered renewed degradation of SMC5\/6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results reveal that therapeutics abrogating all HBV transcripts including HBx promote epigenetic suppression of the HBV minichromosome, whereas strategies protecting the human hepatocytes from reinfection are needed to maintain cccDNA silencing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2020-322571","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T13:56:24Z","timestamp":1611842184000},"page":"372-381","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":75,"title":["Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5\/6 complex and silencing of the viral genome in vivo"],"prefix":"10.1136","volume":"71","author":[{"given":"Lena","family":"Allweiss","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Giersch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pirosu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3120-8958","authenticated-orcid":false,"given":"Tassilo","family":"Volz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"German Center for Infection Research (DZIF), Hamburg-L\u00fcbeck-Borstel-Riems and Heidelberg sites, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C","family":"Muench","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf K","family":"Beran","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Urban","sequence":"additional","affiliation":[{"name":"German Center for Infection Research (DZIF), Hamburg-L\u00fcbeck-Borstel-Riems and Heidelberg sites, Germany"},{"name":"Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Javanbakht","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"L\u00fctgehetmann","sequence":"additional","affiliation":[{"name":"German Center for Infection Research (DZIF), Hamburg-L\u00fcbeck-Borstel-Riems and Heidelberg sites, Germany"},{"name":"Department of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-6689","authenticated-orcid":false,"given":"Maura","family":"Dandri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"German Center for Infection Research (DZIF), Hamburg-L\u00fcbeck-Borstel-Riems and Heidelberg sites, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"2025112102450614000_71.2.372.1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025112102450614000_71.2.372.2","doi-asserted-by":"crossref","DOI":"10.3390\/v9060156","article-title":"The role of cccDNA in HBV maintenance","volume":"9","author":"Allweiss","year":"2017","journal-title":"Viruses"},{"key":"2025112102450614000_71.2.372.3","doi-asserted-by":"crossref","DOI":"10.3390\/v9050125","article-title":"A role for the host DNA damage response in hepatitis B virus cccDNA Formation-and beyond?","volume":"9","author":"Schreiner","year":"2017","journal-title":"Viruses"},{"key":"2025112102450614000_71.2.372.4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coviro.2018.04.003","article-title":"Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination","volume":"30","author":"Dembek","year":"2018","journal-title":"Curr Opin Virol"},{"key":"2025112102450614000_71.2.372.5","doi-asserted-by":"crossref","first-page":"19975","DOI":"10.1073\/pnas.0908365106","article-title":"Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function","volume":"106","author":"Belloni","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112102450614000_71.2.372.6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00281-020-00780-6","article-title":"Epigenetic modulation in chronic hepatitis B virus infection","volume":"42","author":"Dandri","year":"2020","journal-title":"Semin Immunopathol"},{"key":"2025112102450614000_71.2.372.7","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2011.02.015","article-title":"Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection","volume":"55","author":"Lucifora","year":"2011","journal-title":"J Hepatol"},{"key":"2025112102450614000_71.2.372.8","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1099\/vir.0.019224-0","article-title":"HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice","volume":"91","author":"Tsuge","year":"2010","journal-title":"J Gen Virol"},{"key":"2025112102450614000_71.2.372.9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","article-title":"Hepatitis B virus X protein identifies the SMC5\/6 complex as a host restriction factor","volume":"531","author":"Decorsi\u00e8re","year":"2016","journal-title":"Nature"},{"key":"2025112102450614000_71.2.372.10","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.celrep.2016.08.026","article-title":"Hepatitis B virus X protein promotes degradation of Smc5\/6 to enhance HBV replication","volume":"16","author":"Murphy","year":"2016","journal-title":"Cell Rep"},{"key":"2025112102450614000_71.2.372.11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nrm3857","article-title":"The maintenance of chromosome structure: positioning and functioning of SMC complexes","volume":"15","author":"Jeppsson","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025112102450614000_71.2.372.12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.virol.2012.01.021","article-title":"Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication","volume":"426","author":"Hodgson","year":"2012","journal-title":"Virology"},{"key":"2025112102450614000_71.2.372.13","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040834","article-title":"Hepatitis B virus HBx protein mediates the degradation of host restriction factors through the cullin 4 DDB1 E3 ubiquitin ligase complex","volume":"9","author":"Minor","year":"2020","journal-title":"Cells"},{"key":"2025112102450614000_71.2.372.14","doi-asserted-by":"crossref","DOI":"10.3390\/v9040069","article-title":"Identifying and characterizing interplay between hepatitis B virus X protein and Smc5\/6","volume":"9","author":"Livingston","year":"2017","journal-title":"Viruses"},{"key":"2025112102450614000_71.2.372.15","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00769-18","article-title":"Smc5\/6 antagonism by HBx is an evolutionarily conserved function of hepatitis B virus infection in mammals","volume":"92","author":"Abdul","year":"2018","journal-title":"J Virol"},{"key":"2025112102450614000_71.2.372.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169648","article-title":"The SMC5\/6 complex restricts HBV when localized to ND10 without inducing an innate immune response and is counteracted by the HBV X protein shortly after infection","volume":"12","author":"Niu","year":"2017","journal-title":"PLoS One"},{"key":"2025112102450614000_71.2.372.17","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1128\/JVI.01979-15","article-title":"Emerging role of PML nuclear bodies in innate immune signaling","volume":"90","author":"Scherer","year":"2016","journal-title":"J Virol"},{"key":"2025112102450614000_71.2.372.18","doi-asserted-by":"crossref","DOI":"10.3390\/genes10040260","article-title":"Meeting the challenge of eliminating chronic hepatitis B infection","volume":"10","author":"Revill","year":"2019","journal-title":"Genes"},{"key":"2025112102450614000_71.2.372.19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025112102450614000_71.2.372.20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1021\/acsinfecdis.8b00191","article-title":"ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection","volume":"5","author":"Thi","year":"2019","journal-title":"ACS Infect Dis"},{"key":"2025112102450614000_71.2.372.21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"Rnai-Based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025112102450614000_71.2.372.22","doi-asserted-by":"crossref","DOI":"10.1038\/srep15259","article-title":"Combinatorial RNA interference therapy prevents selection of pre-existing HBV variants in human liver chimeric mice","volume":"5","author":"Shih","year":"2015","journal-title":"Sci Rep"},{"key":"2025112102450614000_71.2.372.23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jhep.2015.10.014","article-title":"Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection","volume":"64","author":"Yamamoto","year":"2016","journal-title":"J Hepatol"},{"key":"2025112102450614000_71.2.372.24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2017.09.044","article-title":"Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus","volume":"266","author":"Sato","year":"2017","journal-title":"J Control Release"},{"key":"2025112102450614000_71.2.372.25","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1073\/pnas.0504273102","article-title":"Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids","volume":"102","author":"Wieland","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112102450614000_71.2.372.26","doi-asserted-by":"crossref","first-page":"9332","DOI":"10.1128\/JVI.00918-10","article-title":"Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus","volume":"84","author":"Xu","year":"2010","journal-title":"J Virol"},{"key":"2025112102450614000_71.2.372.27","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jhep.2013.10.021","article-title":"Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during PEGylated interferon-alpha administration","volume":"60","author":"Allweiss","year":"2014","journal-title":"J Hepatol"},{"key":"2025112102450614000_71.2.372.28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J Clin Invest"},{"key":"2025112102450614000_71.2.372.29","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"2025112102450614000_71.2.372.30","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1128\/JVI.01902-09","article-title":"Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction","volume":"84","author":"Schulze","year":"2010","journal-title":"J Virol"},{"key":"2025112102450614000_71.2.372.31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat Biotechnol"},{"key":"2025112102450614000_71.2.372.32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J Hepatol"},{"key":"2025112102450614000_71.2.372.33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J Hepatol"},{"key":"2025112102450614000_71.2.372.34","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00248-19","article-title":"Spatiotemporal analysis of hepatitis B virus X protein in primary human hepatocytes","volume":"93","author":"Kornyeyev","year":"2019","journal-title":"J Virol"},{"key":"2025112102450614000_71.2.372.35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo","volume":"67","author":"Allweiss","year":"2018","journal-title":"Gut"},{"key":"2025112102450614000_71.2.372.36","doi-asserted-by":"crossref","DOI":"10.3390\/v9010018","article-title":"Control of hepatitis B virus by cytokines","volume":"9","author":"Xia","year":"2017","journal-title":"Viruses"},{"key":"2025112102450614000_71.2.372.37","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1172\/JCI83339","article-title":"In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection","volume":"126","author":"Zhang","year":"2016","journal-title":"J Clin Invest"},{"key":"2025112102450614000_71.2.372.38","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/infdis\/jiz607","article-title":"Single hepatocyte hepatitis B virus transcriptional landscape in HIV coinfection","volume":"221","author":"Balagopal","year":"2020","journal-title":"J Infect Dis"},{"key":"2025112102450614000_71.2.372.39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2020.01.028","article-title":"Full-Length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum","volume":"73","author":"Stadelmayer","year":"2020","journal-title":"J Hepatol"},{"key":"2025112102450614000_71.2.372.40","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107533","article-title":"Inducible degradation of the human Smc5\/6 complex reveals an essential role only during interphase","volume":"31","author":"Venegas","year":"2020","journal-title":"Cell Rep"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2020-322571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T10:46:08Z","timestamp":1763721968000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2020-322571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1,11]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/gutjnl-2020-322571"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2020-322571","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]}}}